Core Insights - Changfeng Pharmaceutical (2652.HK), focused on treating respiratory diseases, saw its stock price surge significantly after its listing, with a dark market price increase of 2.2 times [1] Company Performance - The stock reached a peak price of 62 HKD, which is 3.2 times higher than the IPO price of 14.75 HKD, before closing at 48.3 HKD, reflecting a gain of 33.55 HKD or 227.46% [1][2] - The trading volume was 2.9885 million shares, with a total transaction value of 1.49 billion HKD [2] - The average price during trading was 50.005 HKD, with a price fluctuation of 225.09% [2] Financial Metrics - The company has a total market capitalization of 19.899 billion HKD and a total share count of 412 million [2] - The stock's price-to-earnings ratio (P/E) is reported at 661.64 (ITM) and 862.50 (static) [2] - The stock's price-to-book ratio (P/B) stands at 19.038 [2]
长风药业(2652.HK)暗盘收升2.2倍，一手账面赚1.6万港元